A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

Author： MacKenzie Mary   Hirte Holger   Glenwood Goss   Jean Maroun   Goel Rakesh   Major Pierre   Miller Jr. Wilson   Panasci Lawrence   Lorimer Ian   Batist Gerald   Matthews Sarah   Douglas Lynn   Seymour Lesley  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.2, 2005-01, pp. : 165-170

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

By Swaisland H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

By Li Jing   Brahmer Julie   Messersmith Wells   Hidalgo Manuel   Baker Sharyn  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

By Herbst Roy S  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 837-849

Informa Healthcare

Access to resources Recommend Favorite

A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

By Iyer Renuka   Bharthuar Anubha  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 311-320

Informa Healthcare

Access to resources Recommend Favorite